Demonstrates accurate prediction of IDH mutation status in AML using machine learning.
We developed machine-learning models to predict isocitrate dehydrogenase (IDH) mutation status in acute myeloid leukemia (AML) from gene expression profiles and to reconstruct missing IDH annotations across public datasets. Transcriptomic data from 19 cohorts (5844 samples) were harmonized using batch correction, and 1546 samples with known IDH status were used to train a feed-forward neural network and a logistic regression (LR) classifier within a nested cross-validation framework, followed by independent validation in the TCGA-LAML dataset. The LR model showed superior performance, achieving receiver operating characteristic area under the curve $=$ 0.994 ± 0.007, accuracy $=$ 0.983 ± 0.006, balanced accuracy $=$ 0.979 ± 0.005, sensitivity for the IDH-mutant (IDH-MUT) class $=$ 0.972 ± 0.010, and specificity $=$ 0.986 ± 0.008, and correctly classified all IDH-MUT cases in the independent cohort. Applying the final model to samples lacking annotations enabled reconstruction of IDH status for 4148 AML cases, expanding the number of molecularly characterized transcriptomes available for downstream analyses. Predicted groups recapitulated known IDH-associated transcriptional signatures, supporting biological validity. This work demonstrates that IDH mutation status can be accurately inferred from transcriptomic data alone and provides a scalable framework to recover missing genomic annotations, thereby enhancing the utility of public AML resources for large-scale biological and translational research.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: